logo
Fatigue, Brain Fog  And A Racing Heart — What Doctors Are Learning About Post-COVID Neurodivergence

Fatigue, Brain Fog And A Racing Heart — What Doctors Are Learning About Post-COVID Neurodivergence

Forbes16 hours ago
FAIRFAX, VA- February 3 : Eve Efron, who has been struggling with long covid for nearly a year, ... More frequently has to rest on the couch in her home in Fairfax, VA on February 3, 2022. She was denied temporary disability by Mutual of Omaha from her job at a PR firm after her doctor recommended she take time off. Her symptoms include significant fatigue, brain fog, anxiety and depression. (Photo by Carolyn Van Houten/The Washington Post via Getty Images)
Have you ever made people gasp by bending your knees backwards or touching your thumb back to your arm? Does your pulse race when you stand up? Do you have a history of gastric issues or irritable bowel syndrome? Are you also neurodivergent, by any chance?
There is emerging, but compelling, evidence that the overlap between neurodivergence, hypermobility syndromes, mast cell activation syndrome, postural orthostatic tachycardia and dysautonomia is not a coincidence, and has a lot to do with COVID.
The impact of these conditions can be severe on their own, though hard to diagnose and lacking in conclusive biomarkers. They lead to chronic fatigue, serious gastro-intestinal distress, brain fog and concentration difficulties, anxiety and depression. People drop out of the labor force, education and careers are curtailed. Prevalence rates are very hard to come by reliably, but estimates range up to 20% of the population affected by one or more of these conditions. Physicians have noticed that these diagnoses are also rising exponentially since COVID, which appears to trigger or exacerbate symptoms.
An Invisible Problem Hiding In Plain Sight
A special meeting at the Royal Society of Medicine (RSM) in London has concluded that neurodivergent people, who are more likely to have hypermobility, connective tissue and autoimmune conditions, have been disproportionately impacted by COVID, and that this is having a significant impact on our ability to go to school and work. The rise in neurodivergence since 2020 that is placing so much strain on education and health services, the tax payer and not forgetting the individuals themselves and their families, is indeed partly due to increased awareness and more accessible diagnostic criteria – as has already been argued. However, this does not explain why these high rates of diagnosis are accompanied by such vastly increased rates of school absence and inability to work. If neurodivergent people have always existed, why are we only now so unwell that we can't work?
The presentations to the RSM suggested that the effects of COVID on the brain could be contributing to the skyrocketing ADHD and Autism diagnosis waiting lists and to the absence epidemic. Since COVID we've needed to ask for help, whereas before we could fly under the radar.
Some people have dropped out of work or school altogether and are now battling to have their illness recognized. Others are still attending, but battling their own bodies, trying to force themselves to work through increasing difficulties with memory, unpredictable energy levels, pain, unstable pulse rates and various allergic inflammation. Their capacity for their work has been drastically reduced, they don't know why and try as they might to get better, it's not working. They are likely to be prescribed anxiety or depression medication in primary care and go looking for psychological answers to physical problems. Indeed, many of the markers we look for in diagnosing anxiety are, in fact, expressions of our nervous system – pounding heart rate, dizziness, hot / cold flushes. It is too easy to assign symptoms to stress and very difficult to identify the connections across the whole system.
The Solution Is Also Hiding In Plain Sight
It has taken a mixed group of medical experts in immunology, rheumatology, cardiology, urology, psychiatry and neuro-gastroenterology to connect the dots. At the RSM, they presented clear data indicating that for people with this overlapping group of conditions, neurocognitive and emotional symptoms have indeed increased. We're not making it up! Physical symptoms that were triggered by COVID infections have lowered our tolerance for sensory sensitivity in noise, smell, temperature, texture, light, food allergens, mould and all the toxicity in our environment. People who were neurodivergent a decade ago but coping in education and careers are now too ill to do so, and the effects of neuroinflammation could tip a sub-clinical neurotype into diagnosis territory.
The meeting further presented the extraordinary evidence that effective treatments for these issues are already available, such as anti-histamines, probiotics, mast cell stabilisers – simple, cheap, low risk medications which have made the difference between someone working and not working. One of the presenters, Dr Stephanie Barrett, MBChB, MD, FRCP, a Consultant Rheumatologist, reported that non pharmacological and non-invasive treatment such as repeated transcranial magnetic stimulation (rTMS) has also been found to be beneficial. She reports:
"RTMS (neuromodulation) was an extraordinary breakthrough for the treatment of depression. Now using a different protocol, we have shown that we can treat severe fibromyalgia with associated fatigue and dysautonomia, in patients who are stuck for decades in the pain/ fatigue prison.
The additional challenge for our patients is 80% prevalence of neurodivergence. All the complex physical conditions and associations are treatable but they need to be recognised first. We could set up hubs with the government, at low cost to treat all these conditions and return people of all ages to education and the workforce."
Each specialist presented various statistics, using many of the same treatments, indicating that a clear majority of their patients who were neurodivergent and unable to work before treatment are now back in work following an affordable protocol. Careers resumed, stories of people who feel they have 'got their life back'.
Believe People When They Say They Are Ill
In a country where productivity has dived since the financial crisis, and the health of the nation has not recovered from COVID, The Royal Society of Medicine are trying to understand the root causes, rather than paper over the end results. Neurodivergent people are at risk of losing their support from welfare payments due to changes to the benefits system, which could underrate the presence of multiple, mid-level symptoms, even though these all add up to a significant drain. Whilst political circles are arguing over the extent to which the population is malingering versus 'genuinely' ill, this group of physicians have come above the squabbling with a potential lever to tip the system from decline to healing. Following their proposed protocols, we can believe people who say that they can't cope, treat them and support their recovery to living a full life again.
Neurodivergent people of all ages have been stopped in their tracks, creating career and educational hiatuses that cause long term damage. We are at risk of a lost generation of working age people who cannot understand their fatigue, who are trying their hardest but just cannot get moving, the more they try the harder it is (see: post-exertion malaise). If you think you might be affected by any of these conditions, take an inventory of your symptoms, however disjointed they are, and talk to your primary care physician. Even if they can't refer you to a specialist, they owe you an explanation for your difficulties, so remember to be clear about what's happening. It is so easy to write off fatigue and poor concentration as 'stress' – but stress existed before the pandemic. If your capacity has changed, and you feel like it's increasingly hard to cope with work you previously enjoyed or found easy, then this could be a physiological problem and you should speak to your doctor.
Is COVID to blame for the rise in neurodivergence? The answer is complex. We have higher levels of awareness and improved diagnostic criteria. For children, we have failing schools where rigid curricula and draconian discipline disproportionately disadvantage neurodivergent children. In workplaces we have increasing demands for productivity rises and endless escalation of technology and surveillance. All this undoubtedly contributes to the absence epidemic, but all of it started before the pandemic. It doesn't fully explain the stark differences some studies showing that school absence has doubled from 2017 to 2023. The Royal Society of Medicine took some time to come at this problem from a less obvious angle, and in doing so have brought a cost effective solution into the light. It's time to stop assuming that people are lazy and time to stop putting multi-system health issues in the 'too difficult box.' As employers, as a country and as individuals with families to support, we can't afford to ignore the rising absence any longer.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lupita Nyong'o reveals uterine fibroids diagnosis and calls for change
Lupita Nyong'o reveals uterine fibroids diagnosis and calls for change

Yahoo

time26 minutes ago

  • Yahoo

Lupita Nyong'o reveals uterine fibroids diagnosis and calls for change

Lupita Nyong'o has revealed her uterine fibroids diagnosis after "suffering in silence" for over a decade. The 42-year-old actress was diagnosed with the illness - which sees non-cancerous growths developing in or around the uterus - 11 years ago, and she has opened up in a bid to encourage more people to talk about women's health issues. She wrote on Instagram over a series of photos: "In March 2014, I won an Academy Award. That same year, I discovered I had uterine fibroids. 30 fibroids. "I had surgery to remove them. I asked my doctor if I could do anything to prevent them from recurring. "She said: 'You can't. It's only a matter of time until they grow again.' " She explained that uterine fibroids "can range from the size of a pea to as large as a melon", and "can cause heavy menstrual bleeding and anemia, pelvic pain, frequent urination, and complications with pregnancy". One of the slides on The Wild Robot star's post noted that while some women "have no symptoms at all", others will "experience debilitating effects". Lupita pointed out how people "speak so little" of the health issue, despite fibroids impacting 8 out of 10 Black women, and 7 out of 10 white women. She continued: "When we reach puberty, we're taught periods mean pain, and that pain is simply part of being a woman. "I started talking about my experience privately, and I realized so many women are going through this. "We're struggling alone with something that affects us most. No more suffering in silence! We need to stop treating this massive issue like a series of unfortunate coincidences. "We must reject the normalization of female pain. "I envision a future with early education for teenagers, better screening protocols, robust prevention research, and less invasive treatment for uterine fibroids. "Let's study women's health and prioritize this chronic condition that has never been comprehensively examined." The A Quiet Place: Day One actress encouraged her fans to read the caption to the lengthy post, which explained more about Fibroid Awareness Month and revealed she has not only called members of Congress to table a "package of uterine fibroid Congressional bills", as well as teaming up with the Foundation For Women's Health to launch the FWH x Lupita Nyong'o Uterine Fibroid Research Grant. She wrote: "We deserve better. It's time to demand it. Silence serves no one!"

DaVita HealthCare (DVA) Dips More Than Broader Market: What You Should Know
DaVita HealthCare (DVA) Dips More Than Broader Market: What You Should Know

Yahoo

timean hour ago

  • Yahoo

DaVita HealthCare (DVA) Dips More Than Broader Market: What You Should Know

DaVita HealthCare (DVA) closed at $140.53 in the latest trading session, marking a -2.01% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Elsewhere, the Dow lost 0.98%, while the tech-heavy Nasdaq added 0.18%. Heading into today, shares of the kidney dialysis provider had gained 4.04% over the past month, outpacing the Medical sector's loss of 1.56% and lagging the S&P 500's gain of 4.97%. The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. On that day, DaVita HealthCare is projected to report earnings of $2.7 per share, which would represent year-over-year growth of 4.25%. Simultaneously, our latest consensus estimate expects the revenue to be $3.3 billion, showing a 3.5% escalation compared to the year-ago quarter. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $10.76 per share and a revenue of $13.48 billion, indicating changes of +11.16% and +5.15%, respectively, from the former year. Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, DaVita HealthCare boasts a Zacks Rank of #4 (Sell). In terms of valuation, DaVita HealthCare is currently trading at a Forward P/E ratio of 13.33. This represents a discount compared to its industry average Forward P/E of 18.46. We can also see that DVA currently has a PEG ratio of 0.99. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Outpatient and Home Healthcare was holding an average PEG ratio of 1.76 at yesterday's closing price. The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 56, which puts it in the top 23% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

EXCLUSIVE: Supplement Company Cymbiotika Opens First Wellness Café at Fontainebleau Las Vegas
EXCLUSIVE: Supplement Company Cymbiotika Opens First Wellness Café at Fontainebleau Las Vegas

Yahoo

timean hour ago

  • Yahoo

EXCLUSIVE: Supplement Company Cymbiotika Opens First Wellness Café at Fontainebleau Las Vegas

Cymbiotika is headed to Las Vegas. The supplement company, best known for its liposomal packets, is opening its first Cymbiotika Wellness Café at the Fontainebleau's food hall Promenade later this summer. At the café, guests will be able to experience smoothies, juices, açai bowls, yogurt bowls, salads and wraps featuring the brand's supplements. By adding Cymbiotika products to these beverages and meals, guests can opt for a specific health goal, from boosting immunity to supporting focus. There will also be grab-and-go items, as well as Cymbiotika products available. More from WWD How Rising Temperatures Are Raising the Bar for Beauty and Wellness EXCLUSIVE: Nara Smith Fronts Vegamour Hair Supplement Campaign EXCLUSIVE: Kourtney Kardashian Barker's Lemme Is Launching a Greens Gummy Filled With 20 Fruits and Vegetables Some of the brand's bestselling products include Liposomal Vitamin C, $62, and Liposomal Glutathione, $88, and new launches include Liquid Colostrum, $88, and Irish Sea Moss, $65. 'Opening our inaugural Cymbiotika Wellness Café at such an iconic and forward-thinking destination like Fontainebleau Las Vegas is a monumental achievement for us,' said Cymbiotika cofounder and chief executive officer Shahab Elmi in a statement. 'Our mission has always been to empower individuals on their wellness journeys, and this café provides a unique way to experience the benefits of our supplements in a convenient and delicious format. We are excited to be part of Fontainebleau Las Vegas' continued commitment to guest well-being.' While the words Vegas and wellness may seem like polar opposites, the party destination has been getting a bit of a health refresh. For example, in-room IV drips, juice bars and luxe gyms have become the norm along the Strip. 'People aren't really drinking anymore. Vegas once was an absolute party scene, and still is, but I think now… the environment is changing. Everything is about health and supplementation and finding alternatives to drinking but still having a good time,' said cofounder and chief operating officer Durana Elmi. 'Generations now are so much more health-conscious and so much smarter in terms of how they're living their life. They're still having a good time. They're still partying… but they're doing it in a way where they're not damaging their body.' Fountainebleau, in particular, has a NutriDrip IV Lounge, IGK Salon, luxury fitness center and its Lapis Spa and Wellness. In a statement, Michael Waltman, senior vice president of hospitality and nightlife at Fontainebleau, added: 'Health and wellness have always been key pillars of the Fontainebleau Las Vegas guest experience. From the award-winning Lapis Spa & Wellness to our innovative fitness center, we pride ourselves on being a leader in wellness tourism with our best-in-class amenities and offerings. This partnership with Cymbiotika brings a natural synergy across our culinary, spa and fitness offerings, furthering our commitment to delivering a holistic and enriching stay at every touchpoint.' The Cymbiotika Wellness Café is expected to open late summer.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store